{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:20Z","timestamp":1794049640828,"version":"4.8.0"},"reference-count":17,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004856","name":"New York State Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Since 2014, cannabidiol (\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      ) has been administered to patients with treatment\u2010resistant epilepsies (\n                      <jats:styled-content style=\"fixed-case\">TREs<\/jats:styled-content>\n                      ) in an ongoing expanded\u2010access program (\n                      <jats:styled-content style=\"fixed-case\">EAP<\/jats:styled-content>\n                      ). We report interim results on the safety and efficacy of\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      in\n                      <jats:styled-content style=\"fixed-case\">EAP<\/jats:styled-content>\n                      patients treated through December 2016.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010five\n                      <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\n                      \u2010based\n                      <jats:styled-content style=\"fixed-case\">EAP<\/jats:styled-content>\n                      sites enrolling patients with\n                      <jats:styled-content style=\"fixed-case\">TRE<\/jats:styled-content>\n                      taking stable doses of antiepileptic drugs (\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s) at baseline were included. During the 4\u2010week baseline period, parents\/caregivers kept diaries of all countable seizure types. Patients received oral\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      starting at 2\u201010 mg\/kg\/d, titrated to a maximum dose of 25\u201050 mg\/kg\/d. Patient visits were every 2\u20104 weeks through 16 weeks and every 2\u201012 weeks thereafter. Efficacy endpoints included the percentage change from baseline in median monthly convulsive and total seizure frequency, and percentage of patients with \u226550%, \u226575%, and 100% reductions in seizures vs baseline. Data were analyzed descriptively for the efficacy analysis set and using the last\u2010observation\u2010carried\u2010forward method to account for missing data. Adverse events (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s) were documented at each visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 607 patients in the safety dataset, 146 (24%) withdrew; the most common reasons were lack of efficacy (89 [15%]) and\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s (32 [5%]). Mean age was 13 years (range, 0.4\u201062). Median number of concomitant\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s was 3 (range, 0\u201010). Median\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      dose was 25 mg\/kg\/d; median treatment duration was 48 weeks. Add\u2010on\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks; reductions were similar through 96 weeks. Proportion of patients with \u226550%, \u226575%, and 100% reductions in convulsive seizures were 52%, 31%, and 11%, respectively, at 12 weeks, with similar rates through 96 weeks.\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      was generally well tolerated; most common\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s were diarrhea (29%) and somnolence (22%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>\n                      Results from this ongoing\n                      <jats:styled-content style=\"fixed-case\">EAP<\/jats:styled-content>\n                      support previous observational and clinical trial data showing that add\u2010on\n                      <jats:styled-content style=\"fixed-case\">CBD<\/jats:styled-content>\n                      may be an efficacious long\u2010term treatment option for\n                      <jats:styled-content style=\"fixed-case\">TRE<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/epi.14477","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T04:03:47Z","timestamp":1531368227000},"page":"1540-1548","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["Long\u2010term safety and treatment effects of cannabidiol in children and adults with treatment\u2010resistant epilepsies: Expanded access program results"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-6627","authenticated-orcid":false,"given":"Jerzy P.","family":"Szaflarski","sequence":"first","affiliation":[{"name":"University of Alabama Birmingham Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Martina","family":"Bebin","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Comi","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-1541","authenticated-orcid":false,"given":"Anup D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-7242","authenticated-orcid":false,"given":"Charuta","family":"Joshi","sequence":"additional","affiliation":[{"name":"University of Iowa Children's Hospital Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Checketts","sequence":"additional","affiliation":[{"name":"GW Research Ltd London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4748-9248","authenticated-orcid":false,"given":"Jules C.","family":"Beal","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center and Albert Einstein College in Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Laux","sequence":"additional","affiliation":[{"name":"Ann &amp; Robert H. Lurie Children's Hospital of Chicago Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"De Boer","sequence":"additional","affiliation":[{"name":"Greenwich Biosciences Inc. Carlsbad CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Wong","sequence":"additional","affiliation":[{"name":"Wake Forest Baptist Medical Center Winston\u2010Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick","family":"Lopez","sequence":"additional","affiliation":[{"name":"Loma Linda University Children's Hospital Loma Linda CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[{"name":"NYU Langone's Comprehensive Epilepsy Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Lyons","sequence":"additional","affiliation":[{"name":"Virginia Comprehensive Epilepsy Program Winchester VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Pichon","family":"Zentil","sequence":"additional","affiliation":[{"name":"Loma Linda University Children's Hospital Loma Linda CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wechsler","sequence":"additional","affiliation":[{"name":"Consultants in Epilepsy &amp; Neurology PLLC and Idaho Comprehensive Epilepsy Center Boise ID USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CBD EAP study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611618"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00379-8"},{"key":"e_1_2_8_4_1","first-page":"e100","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox\u2010Gastaut syndrome (LGS): results of a dose\u2010ranging, multi\u2010center, randomized, double\u2010blind, placebo\u2010controlled trial (GWPCARE3)","volume":"89","author":"Patel A","year":"2017","journal-title":"Neurology"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.03.001"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.159145"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816669450"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13499"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.10.008"},{"key":"e_1_2_8_11_1","unstructured":"Janssen Korea Ltd.An observational study to evaluate long\u2010term retention rate of topiramate in participants with epilepsy 2013. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01682681."},{"key":"e_1_2_8_12_1","first-page":"S155","article-title":"Improvement in quality of life ratings after one year of treatment with pharmaceutical formulation of cannabidiol (CBD)","volume":"58","author":"Gaston T","year":"2017","journal-title":"Epilepsia"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13815"},{"key":"e_1_2_8_14_1","unstructured":"DeWolfeJL BebinEM CutterGR et al.Effects of pharmaceutical grade cannabidiol on seizure frequency. American Epilepsy Society Abstracts Database (Abst. 2.100). Available from:https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/195499Accessed May 7 2018."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13852"},{"key":"e_1_2_8_16_1","unstructured":"SommervilleK CrockettJ BlakeyGE MorrisonG.Bidirectional drug\u2010drug interaction with coadministration of cannabidiol and clobazam in a phase 1 healthy volunteer trial. American Epilepsy Society Abstracts Database (Abst. 1.433). Available from:https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/381188Accessed May 7 2018."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005254"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2017.10.001"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T12:38:36Z","timestamp":1694954316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/epi.14477"],"URL":"https:\/\/doi.org\/10.1111\/epi.14477","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733629419.793556787","asserted-by":"object"}]},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"2018-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}